Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7146-7154

  Xue, Hongyu ^a   Sawyer, Michael B ^a   Field, Catherine J ^a   Dieleman, Levinus A ^a   Baracos, Vickie E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BETA GLUCURONIDASE; GLUTAMINE; IRINOTECAN; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; PREBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; COLITIS; COLON TUMOR; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXPERIMENTAL RAT; FEMALE; GASTROINTESTINAL TOXICITY; LIFESTYLE MODIFICATION; LIPID DIET; MORBIDITY; NONHUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; RAT; SCORING SYSTEM; STANDARDIZATION;

ANIMALS; CAMPTOTHECIN; COLONIC NEOPLASMS; DIARRHEA; DIET; FATTY ACIDS, OMEGA-3; FEMALE; FOOD-DRUG INTERACTIONS; GLUTAMINE; OLIGOSACCHARIDES; PROBIOTICS; RATS;

EID: 37249025092     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0823     Document Type: Article

References (50)

1. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 2001;6:66-80.
2. Rosen LS. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park) 1998;12:103-9.
3. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Cur Med Chem 2003;10:41-9.
4. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-7.
5. Hardman WE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 1999;81:440-8.
6. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401-12.
7. Macdonald A. Omega-3 fatty acids as adjunctive therapy in Crohns disease. Gastroenterol Nurs 2006;29:295-301; quiz 2-3.
8. Lai YN, Yeh SL, Lin MT, Shang HF, Yeh CL, Chen WJ. Glutamine supplementation enhances mucosal immunity in rats with gut-derived sepsis. Nutrition 2004;20:286-91.
9. Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006;12:5941-50.
10. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29:501-13.
11. Ziegler TR. Glutamine supplementation in bone marrow transplantation. Br J Nutr 2002;87 Suppl 1:S9-15.
12. Baracos V, Mazurak V, Ma D. n-3 polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 2004;17:1-17.
13. Conklin KA. Dietary polyunsaturated fatty acids: impact on cancer chemotherapy and radiation. Altern Med Rev 2002;7:4-21.
14. Funk MA, Baker DH. Effect of fiber, protein source and time of feeding on methotrexate toxicity in rats. J Nutr 1991;121:1673-83.
15. Kimura Y, Okuda H. Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice. Jpn J Cancer Res 1999;90:765-74.
16. Souba WW. Therapeutic applications of glutamine. J Nutr 2001;131:discussion 2590S.
17. Labow BI, Souba WW. Glutamine. World J Surg 2000;24:1503-13.
18. Cao S, Black JD, Troutt AB, Rustum YM. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 1998;58:3270-4.
19. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23.
20. van Leeuwen IM, Zonneveld C. From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis. Mutat Res 2001;489:17-45.
21. Robinson LE, Clandinin MT, Field CJ. The role of dietary long-chain n-3 fatty acids in anti-cancer immune defense and R3230AC mammary tumor growth in rats: influence of diet fat composition. Breast Cancer Res Treat 2002;73:145-60.
22. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB. Glutamine induces heat shock protein and protects against endotoxin shock in the rat. J Appl Physiol 2001;90:2403-10.
23. Singleton KD, Wischmeyer PE. Oral glutamine enhances heat shock protein expression and improves survival following hyperthermia. Shock 2006;25:295-9.
24. Hoentjen F, Welling GW, Harmsen HJ, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005;11:977-85.
25. Videla S, Vilaseca J, Antolin M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001;96:1486-93.
26. Le Blay G, Michel C, Blottiere HM, Cherbut C. Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in cecal butyrate in rats. J Nutr 1999;129:2231-5.
27. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
28. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
29. Sedgwick GW, Fenton TF, Thompson JR. Effect of protein precipitating agents on the recovery of plasma free amino acids. Can J Anim Sci 1991;71:953-7.
30. Field CJ, Toyomizu M, Clandinin MT. Relationship between dietary fat, adipocyte membrane composition and insulin binding in the rat. J Nutr 1989;119:1483-9.
31. Freeman HJ. Effects of differing purified cellulose, pectin, and hemicellulose fiber diets on fecal enzymes in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Cancer Res 1986;46:5529-32.
32. James LA, Lunn PG, Elia M. Glutamine metabolism in the gastrointestinal tract of the rat assess by the relative activities of glutaminase (EC 3.5.1.2) and glutamine synthetase (EC 6.3.1.2). Br J Nutr 1998;79:365-72.
33. James LA, Lunn PG, Middleton S, Elia M. Distribution of glutaminase and glutamine synthetase activities in the human gastrointestinal tract. Clin Sci (Lond) 1998;94:313-9.
34. Shou J, Lieberman MD, Hofmann K, et al. Dietary manipulation of methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr 1991;15:307-12.
35. Kanauchi O, Mitsuyama K, Saiki T, Agata K, Nakamura T, Iwanaga T. Preventive effects of germinated barley foodstuff onmethotrexate-induced enteritis in rats. Int J Mol Med 1998;1:961-6.
36. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001;61:687-93.
37. Landel AM, Hammond WG, Meguid MM. Aspects of amino acid and protein metabolism in cancer-bearing states. Cancer 1985;55:230-7.
38. Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 2001;48:28-33.
39. Sakai H, Sato T, Hamada N, et al. Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon. J Physiol 1997;505:133-44.
40. Kase Y, Hayakawa T, Togashi Y, Kamataki T. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacol 1997;75:399-405.
41. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505-19S.
42. Lim CC, Ferguson LR, Tannock GW. Dietary fibres as "prebiotics" : implications for colorectal cancer. Mol Nutr Food Res 2005;49:609-19.
43. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-9.
44. Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004;20:146-55.
45. Meier R, Burri E, Steuerwald M. The role of nutrition in diarrhoea syndromes. Curr Opin Clin Nutr Metab Care 2003;6:563-7.
46. Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003;14:805-6.
47. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-41.
48. Murphy MG, Wright V, Ackman RG, Horackova M. Diets enriched in menhaden fish oil, seal oil, or shark liver oil have distinct effects on the lipid and fatty-acid composition of guinea pig heart. Mol Cell Biochem 1997;177:257-69.
49. Robinson LE, Clandinin MT, Field CJ. R3230AC rat mammary tumor and dietary long-chain (n-3) fatty acids change immune cell composition and function during mitogen activation. J Nutr 2001;131:2021-7.
50. Gilman J, Cashman KD. The effect of marine oil-derived n-3 fatty acids on transepithelial calcium transport in Caco-2 cell models of healthy and inflamed intestines. Br J Nutr 2007;97:281-8.